` IRD (Opus Genetics Inc) vs S&P 500 Comparison - Alpha Spread

IRD
vs
S&P 500

Over the past 12 months, IRD has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +13% growth.

Stocks Performance
IRD vs S&P 500

Loading
IRD
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
IRD vs S&P 500

Loading
IRD
S&P 500
Difference
www.alphaspread.com

Performance By Year
IRD vs S&P 500

Loading
IRD
S&P 500
Add Stock

Competitors Performance
Opus Genetics Inc vs Peers

Opus Genetics Inc
Glance View

Market Cap
71m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

IRD Intrinsic Value
1.75 USD
Undervaluation 32%
Intrinsic Value
Price
Back to Top